Dean Y. Li - 03 Jan 2022 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/ Nathan Hatfield, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
03 Jan 2022
Transactions value $
$0
Form type
4
Filing time
05 Jan 2022, 19:46:30 UTC
Previous filing
09 Dec 2021
Next filing
28 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Award $0 +659 +0.11% $0.000000 597,922 03 Jan 2022 Direct F1
holding RXRX Class A Common Stock 1,316,000 03 Jan 2022 By Dean Y. Li 2021 GRAT
holding RXRX Class A Common Stock 1,315,000 03 Jan 2022 By Dean Y. Li 2021 GRAT
holding RXRX Class A Common Stock 1,422,048 03 Jan 2022 By Dean Li and Ruth Li Revocable Trust
holding RXRX Class A Common Stock 450,000 03 Jan 2022 By Dean Y. Li 2021 Family Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.